Table 2 Baseline characteristics of included participants
ID | Duration | Dose | Age (years), M (SD) | Time since onset of SLE, M (SD) | Concomitant medications | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glucocorticoids, N (%) | Prednisone dose (mg/day), M (SD) | Antimalarials, N (%) | Immunosuppressants, N (%) | Methotrexate, N (%) | Azathioprine, N (%) | Mycophenolate mofetil, N (%) | NSAIDs, N (%) | |||||
Petri 2023 | 52 weeks | 2 mg | 42·8 (13·0) | 8·7 (7·7) | 210 (80%) | 9·6 (5·9) | 213 (82%) | 133 (51%) | 52 (20%) | 48 (18%) | 25 (10%) | 64 (25%) |
4 mg | 42·2 (12·1) | 8·5 (7·7) | 207 (80%) | 9·8 (5·7) | 213 (83%) | 133 (52%) | 60 (23%) | 33 (13%) | 25 (10%) | 70 (27%) | ||
Placebo | 43·5 (13·5) | 9·0 (8·3) | 207 (81%) | 8·8 (5·0) | 209 (82% | 140 (55%) | 49 (19%) | 47 (18%) | 29 (11%) | 51 (20%) | ||
Morand 2023 | 52 weeks | 2 mg | 42·9 (12·4) | 9·2 (7·7) | 194 (76%) | 10·4 (7) | 189 (74%) | 152 (60%) | 51 (20%) | 54 (21%) | 39 (15%) | 67 (26%) |
4 mg | 41·5 (12·9) | 8·8 (8·2) | 187 (74%) | 10·1 (6) | 206 (82%) | 141 (56%) | 52 (21%) | 42 (17%) | 34 (14%) | 68 (27%) | ||
Placebo | 42·0 (12·0) | 9·4 (7·5) | 195 (77%) | 9·8 (5) | 213 (84%) | 150 (59%) | 60 (24%) | 38 (15%) | 39 (15%) | 63 (25%) | ||
Wallace 2018 | 24 weeks | 2 mg | 43·2 (11·0) | 11·8 (9·1) | 79 (75%) | 8·7 (5·8) | 71 (68%) | 47 (45%) | 17 (16%) | 10 (10%) | 10 (10%) | 29 (28%) |
4 mg | 45·0 (12·4) | 11·5 (10·3) | 74 (71%) | 10·5 (17·4) | 76 (73%) | 50 (48%) | 13 (13%) | 11 (11%) | 16 (15%) | 32 (31%) | ||
Placebo | 44·9 (12·8) | 9·7 (7·7) | 77 (73%) | 7·9 (4·6) | 75 (71%) | 45 (43%) | 13 (12%) | 15 (14%) | 11 (10%) | 27 (26%) | ||
SLEDAI-2 K score, M (SD) | SLEDAI-2 K score ≥ 10, N (%) | SLEDAI-2 K organ system involvement | PGA score, M (SD) | CLASI activity score, M (SD) | ||||||||
CNS, N (%) | Vascular, N (%) | Musculoskeletal, N (%) | Renal, N (%) | Mucocutaneous, N (%) | Cardiovascular and respiratory, N (%) | Immunological, N (%) | Constitutional, N (%) | Hematological, N (%) | ||||
10·1 (3·4) | 149 (57%) | 0 | 11 (4%) | 253 (97%) | 22 (8%) | 252 (97%) | 6 (2%) | 143 (55%) | 10 (4%) | 19 (7%) | 61·0 (12·5) | 6·6 (6·6) |
10·1 (3·0) | 144 (56%) | 0 | 14 (5%) | 251 (97%) | 10 (4%) | 251 (97%) | 9 (3%) | 132 (51%) | 11 (4%) | 17 (7%) | 58·8 (14·6) | 6·7 (5·8) |
10·1 (3·2) | 147 (57%) | 0 | 12 (5%) | 252 (98%) | 18 (7%) | 243 (95%) | 4 (2%) | 138 (54% | 8 (3%) | 20 (8%) | 60·0 (14·6) | 6·8 (6·1) |
10·3 (3) | 152 (60%) | 0 | 15 (6%) | 250 (98%) | 24 (9%) | 246 (97%) | 6 (2%) | 131 (51%) | 3 (1%) | 13 (5%) | 1·8 (0·4) | 6·5 (7·0) |
10·0 (3) | 146 (58%) | 0 | 10 (4%) | 247 (98%) | 17 (7%) | 241 (96%) | 8 (3%) | 137 (54%) | 2 (1%) | 21 (8%) | 1·8 (0·5) | 6·1 (5·6) |
10·1 (3) | 144 (57%) | 0 | 15 (6%) | 247 (98%) | 15 (6%) | 244 (96%) | 10 (4%) | 134 (53%) | 4 (2%) | 13 (5%) | 1·8 (0·5) | 6·3 (6·2) |
8·8 (3·4) | 35 (33%) | 1 (1%) | 4 (4%) | 93 (89%) | 9 (9%) | 82 (78%) | 1 (1%) | 63 (60%) | 2 (2%) | 9 (9%) | 48·8 (15·8) | 3·8 (5·4) |
9·0 (3·3) | 44 (42% | 2 (2%) | 3 (3%) | 96 (92%) | 7 (7%) | 92 (88%) | 1 (1%) | 64 (62%) | 0 | 5 (5%) | 51·7 (16·0) | 4·0 (3·4) |
8·9 (2·9) | 43 (41%) | 3 (3%) | 1 (1%) | 93 (89%) | 9 (9%) | 90 (86%) | 2 (2%) | 62 (59%) | 2 (2%) | 13 (12%) | 49·5 (16·9) | 4·9 (5·7) |
TJC, M (SD) | SJC, M (SD) | SLICC/ACR Damage Index score, m (SD) | ||||||||||
10·3 (6·8) | 6·64 (5·1) | 0·68 (1·1) | ||||||||||
10·6 (7·1) | 6·68 (5·0) | 0·60 (1·0) | ||||||||||
10·6 (7·1) | 6·41 (5·4) | 0·66 (1·1) | ||||||||||
10·3 (6·5) | 6·9 (5·1) | 0·6 (1·0) | ||||||||||
10·9 (7·0) | 6·9 (5·4) | 0·6 (1·0) | ||||||||||
10·0 (7·0) | 7·1 (5·6) | 0·6 (1·0) | ||||||||||
8·7 (6·6) | 5·2 (4·7) | 0·44 (0·68) | ||||||||||
8·5 (6·2) | 5·5 (4·2) | 0·40 (0·88) | ||||||||||
7·7 (5·8) | 5·3 (4·7) | 0·59 (0·97) | ||||||||||